Shots:

• The approval is based on the P-III ADVOCATE trial that evaluates Tavneos in 330 patients with ANCA-associated vasculitis across 20 countries. Patients were randomized to receive either rituximab or cyclophosphamide & Tavneos or prednisone
• The study met its 1EPs of disease remission @26wks. and sustained remission @52wks. as assessed by BVAS. The study also showed superiority to a prednisone-based SoC for sustained remission
• Avneos is a selective complement 5a receptor inhibitor & is also approved to treat MPA & granulomatosis with polyangiitis in Japan. The regulatory decision in the EU follows the EMA review which is expected at the end of 2021

Click here to­ read full press release/ article | Ref: ChemoCentryx | Image: LinkedIn